Asset profile

Calderasib

Small molecule

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2029-02-19.

How the evidence outlook works ↗

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2029 (3)
February 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-19 · NCT06345729 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

August 2029 (1)
Phase 1/2Lung Neoplasm MalignantRecruiting
Est. primary completion 2029-08-17 · NCT07286149 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2029 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12-07 · NCT07190248 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2032 (2)
April 2032 (1)
Phase 2Neoplasm MalignantRecruiting
Est. primary completion 2032-04-09 · NCT07209111 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2032 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-12-15 · NCT07554339 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2033 (1)
January 2033 (1)
Phase 2Malignant NeoplasmRecruiting
Est. primary completion 2033-01-14 · NCT07252739 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2039 (1)
October 2039 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2039-10-26 · NCT07431827 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.